We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$337M
AUM Growth
+$3.84M
Cap. Flow
-$22.8M
Cap. Flow %
-6.78%
Top 10 Hldgs %
34.36%
Holding
109
New
18
Increased
35
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$9.48M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.12M
3
CAH icon
Cardinal Health
CAH
+$6.74M
4
AGN
Allergan plc
AGN
+$5.18M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.64M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.87M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
CFNL
Cardinal Financial Corp
CFNL
+$5.03M
5
FRX
FOREST LABORATORIES INC
FRX
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
2 Financials 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
101
CALL
Johnson & Johnson
JNJ
$625B
– –
-50,000
Closed -$4.91M
JNJ icon
102
Johnson & Johnson
JNJ
$625B
– –
-19,481
Closed -$1.91M
MDT icon
103
Medtronic
MDT
$112B
– –
-39,429
Closed -$2.43M
PFE icon
104
Pfizer
PFE
$153B
– –
-372,050
Closed -$11.3M
LUMO
105
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-2,178
Closed -$557K
AUXL
106
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-63,875
Closed -$1.74M
FRX
107
DELISTED
FOREST LABORATORIES INC
FRX
– –
-48,152
Closed -$4.44M
CFNL
108
DELISTED
Cardinal Financial Corp
CFNL
– –
-71,909
Closed -$5.03M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rhenman & Partners Asset Management held 109 positions worth $337M, up 1.2% from $333M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $22.8M in Q2 2014, closing 13 positions and reducing 37 holdings. Its most notable exit was Pfizer, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Vertex Pharmaceuticals worth $9.62M.

  • Rhenman & Partners Asset Management's largest Q2 2014 buy was Vertex Pharmaceuticals: 101,600 shares worth $9.62M.
  • Rhenman & Partners Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q2 2014, an estimated $9.48M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.87M.
  • Rhenman & Partners Asset Management fully exited Pfizer in Q2 2014, selling an estimated $11.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $337M portfolio in Q2 2014.
  • Rhenman & Partners Asset Management opened 18 new positions and closed 13 in Q2 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.2% quarter-over-quarter to $337M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.